此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

自身免疫性肺泡蛋白沉积症 (aPAP) 吸入 Molgramostim 雾化溶液的临床试验 (IMPALA-2)

2026年10月10日 更新者:Savara Inc.

每日一次吸入 Molgramostim 雾化器溶液在患有自身免疫性肺泡蛋白沉积症 (aPAP) 的成人受试者中的随机、双盲、安慰剂对照临床试验

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

研究概览

详细说明

This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.

An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.

The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.

研究类型

介入性

注册 (实际的)

164

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N 4N1
        • University of Calgary
    • Ontario
      • Hamilton、Ontario、加拿大、L8N 4A6
        • St Joseph's Healthcare Hamilton Research
    • Quebec
      • Québec、Quebec、加拿大、G1V 4G5
        • University Institute of Cardiology and Respirology of Quebec
    • Ankara
      • Ankara、Ankara、土耳其(türkiye)、6010
        • Health Sciences University Gulhane Training and Research Hospital
    • Istanbul
      • Istanbul、Istanbul、土耳其(türkiye)、34020
        • Yedikule Chest Disease and Surgery Training and Research Hospital
    • İzmir
      • Bornova、İzmir、土耳其(türkiye)、35100
        • Ege University Hospital - Department of Pulmonology
      • Athens、希腊、12462
        • Attikon University Hospital
    • Baden-Wurttemberg
      • Heidelberg、Baden-Wurttemberg、德国、69126
        • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
    • Bavaria
      • Muenchen-Gauting、Bavaria、德国、82131
        • Asklepios Fachkliniken Muenchen-Gauting
    • North Rhine-Westphalia
      • Essen、North Rhine-Westphalia、德国、45239
        • Ruhrlandklinik Westdeutsches Lungenzentrum
    • Lombardy
      • Pavia、Lombardy、意大利、27100
        • Fondazione IRCCS Policlinico San Matteo
      • Nagakute、日本、480-1195
        • Aichi Medical University Hospital
    • Chiba
      • Chiba、Chiba、日本、260-8677
        • Chiba University Hospital - Respiratory Medicine
    • Hokkaidô
      • Sapporo、Hokkaidô、日本、060-8648
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama、Kanagawa、日本、236-0051
        • Kanagawa Cardiovascular and Respiratory Center
    • Kumamoto
      • Kumamoto、Kumamoto、日本、860-8556
        • Kumamoto University Hospital
    • Miyagi
      • Sendai、Miyagi、日本、980-8574
        • Tohoku University Hospital - Respiratory Tract Medicine
    • Osaka
      • Sakai、Osaka、日本、591-8555
        • National Hospital Organization Kinki-Chuo Chest medical Center
    • Saitama
      • Saitama、Saitama、日本、330-8553
        • Saitama Red Cross Hospital
    • Tokyo
      • Mitaka、Tokyo、日本、181-8611
        • Kyorin University Hospital
    • Brussels Capital
      • Brussels、Brussels Capital、比利时、1070
        • Hôpital Erasme
    • Vlaams Brabant
      • Leuven、Vlaams Brabant、比利时、3000
        • UZ Leuven - Campus Gasthuisberg - Pneumologie
    • Auvergne-Rhône-Alpes
      • Bron、Auvergne-Rhône-Alpes、法国、69500
        • Hôpital Louis Pradel
    • Brittany Region
      • Rennes、Brittany Region、法国、35033
        • CHU Pontchaillou
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、波兰、01-138
        • Instytut Gruzlicy i Chorob Pluc
    • New South Wales
      • Camperdown、New South Wales、澳大利亚、2050
        • Royal Prince Alfred Hospital
      • Westmead、New South Wales、澳大利亚、2145
        • Westmead Hospital
      • Dublin、爱尔兰、DO4 T6F4
        • St. Vincent's University Hospital
    • Bucharest
      • Bucharest、Bucharest、罗马尼亚、050159
        • Institutul de Pneumoftiziologie "Marius Nasta"
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • University Of Arkansas For Medical Services
    • California
      • Los Angeles、California、美国、90095
        • UCLA David Geffen School of Medicine
    • Colorado
      • Denver、Colorado、美国、80206
        • National Jewish Health
    • Connecticut
      • New Haven、Connecticut、美国、06520
        • Yale University
    • Florida
      • Gainesville、Florida、美国、32610
        • University of Florida Health
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University
    • Illinois
      • Maywood、Illinois、美国、60153
        • Loyola University
    • Maryland
      • Baltimore、Maryland、美国、21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University in St. Louis
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke University Medical Center
      • Raleigh、North Carolina、美国、27610
        • Wake Med Health & Hospital
    • Ohio
      • Cincinnati、Ohio、美国、45229-3039
        • Cincinnati Children's Hospital Medical Center
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania Perelman School of Medicine - Pulmonology
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh
    • Texas
      • Dallas、Texas、美国、75390
        • UT Southwestern Medical Center
    • London
      • London、London、英国、SW3 6NP
        • Royal Brompton and Harefield NHS Foundation Trust
    • Utrecht
      • Nieuwegein、Utrecht、荷兰、3435CM
        • St Antonius Hospital
    • Lisbon District
      • Lisbon、Lisbon District、葡萄牙、1769-001
        • Hospital Pulido Valente
    • Porto District
      • Porto、Porto District、葡萄牙、4200-319
        • Hospital São João
    • Catalonia
      • Barcelona、Catalonia、西班牙、08907
        • Hospital Universitario de Bellvitge
      • Seoul、韩国、03080
        • Seoul National University Hospital
      • Seoul、韩国、05505
        • Asan Medical Center
      • Seoul、韩国、06351
        • Samsung Medical Center
      • Seoul、韩国、03722
        • Severance Hospital - Yonsei University Health System - Pulmonary

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).

  2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.

  3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.

  4. A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.

  5. Change in %DLCO adj of <15% points during the screening period.

  6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).

  7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.

  8. Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.

  9. Male or female

  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
    2. Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
  11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.

Exclusion Criteria:

  1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
  2. Whole lung lavage (WLL) performed within 3 months prior to baseline.
  3. Requirement for WLL at screening or baseline.
  4. GM-CSF treatment within 6 months prior to baseline.
  5. Treatment with rituximab within 6 months prior to baseline.
  6. Treatment with plasmapheresis within 6 weeks prior to baseline.
  7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
  8. Previously randomized in this trial.
  9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
  10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
  11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
  12. History of, or present, myeloproliferative disease or leukemia.
  13. Apparent pre-existing concurrent pulmonary fibrosis.
  14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
  15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
  16. Physical disability or other condition that precludes safe and adequate exercise testing.
  17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
  18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
  19. For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Molgramostim

Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks

Molgramostim 300 µg nebulizer solution

其他名称:
  • 重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)
安慰剂比较:Placebo

Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks

Matching placebo nebulizer solution

其他名称:
  • 安慰剂雾化器
实验性的:Molgramostim Open-label Extension

Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks

Molgramostim 300 µg nebulizer solution

其他名称:
  • 重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
大体时间:From Baseline to Week 24

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj).

From Baseline to Week 24

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
大体时间:From Baseline to Week 48

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange.

From Baseline to Week 48
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
大体时间:From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 24
Change From Baseline in SGRQ Activity Component Score to Week 24
大体时间:From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 24
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
大体时间:From Baseline to Week 24

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 24
Change From Baseline in SGRQ Total Score to Week 48
大体时间:From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 48
Change From Baseline in SGRQ Activity From Baseline to Week 48
大体时间:From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 48
Change From Baseline in EC, Expressed as Peak METs to Week 48
大体时间:From Baseline to Week 48

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 48
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
大体时间:From Baseline to Week 24

A-aDO2 was used as an additional measure of gas exchange.

From Baseline to Week 24
Number of Subjects With Serious and Non-serious Adverse Events
大体时间:From Baseline until End of Double-blind treatment (Week 48)

Assessment of the safety of molgramostim compared to placebo

From Baseline until End of Double-blind treatment (Week 48)
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
大体时间:From Baseline until End of Double-blind treatment Week-48

Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline).

From Baseline until End of Double-blind treatment Week-48
Changes in Forced Vital Capacity (FVC) %Predicted Normal
大体时间:From Baseline to Weeks 24 and 48

Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity.

From Baseline to Weeks 24 and 48
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
大体时间:From Baseline to Weeks 24 and 48

FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function.

From Baseline to Weeks 24 and 48
Change in QT Interval Corrected by Fridericia (QTcF)
大体时间:From Baseline to Weeks 4 and 24

Assessment of the safety of MOL compared to placebo

From Baseline to Weeks 4 and 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Bruce Trapnell, MD、Children's Hospital Medical Center, Cincinnati

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年5月19日

初级完成 (实际的)

2023年11月30日

研究完成 (估计的)

2027年5月30日

研究注册日期

首次提交

2020年9月3日

首先提交符合 QC 标准的

2020年9月3日

首次发布 (实际的)

2020年9月10日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月10日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅